

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): June 24, 2022**

---

**INHIBIKASE THERAPEUTICS, INC.**  
(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-39676**  
(Commission  
File Number)

**26-3407249**  
(IRS Employer  
Identification No.)

**3350 Riverwood Parkway SE, Suite 1900**  
**Atlanta, Georgia**  
(Address of Principal Executive Offices)

**30339**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (678) 392-3419**

N/A  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
-

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value	IKT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The 2022 Annual Meeting of Stockholders (“Annual Meeting”) of Inhibikase Therapeutics, Inc. (the “Company”) was held on June 24, 2022. The following proposals were approved at the Annual Meeting by the votes indicated:

Proposal One: To elect two directors to the board of directors of the Company to serve as Class II directors, to serve until the Company’s 2025 annual meeting of stockholders or until in each case their respective successor is duly elected and qualified. The nominees for election were Roy Freeman, M.D and Paul Grint, M.D.

The following nominees were elected by the votes indicated to serve as Class II directors, to serve until the Company’s 2025 annual meeting of stockholders or until their respective successors are duly elected and qualified:

Name	Total Votes for Director	Total Votes Withheld from Director	Total Broker Non-Votes
Roy Freeman, M.D.	11,443,604	574,448	4,467,473
Paul Grint, M.D.	11,530,376	487,676	4,467,473

Proposal Three: To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

	Total Votes
For	16,397,389
Against	31,521
Abstain	56,614
Broker Non-Votes	0

The following proposal was not adopted at the Annual Meeting by the votes indicated because the requisite approval percentage was not met:

Proposal Two: To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000.

	<b>Total Votes</b>
For	15,007,293
Against	1,428,440
Abstain	49,792
Broker Non-Votes	0

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 29, 2022

INHIBIKASE THERAPEUTICS, INC.

By: /S/ MILTON H. WERNER  
Milton H. Werner, Ph.D.  
President and Chief Executive Officer

